|  |  | Cmin | Cmax | ||||
---|---|---|---|---|---|---|---|---|
Antiretroviral agent | Â | n | n (%) >1.5 historical pop Mean | Media ratio to historical population mean median ratio (IQR) | p-value a | n (%) >1.5 Historical pop mean | Media ratio to historical population mean Median ratio ( IQR) | p-value a |
All | Â | 82 | 28 (34.1%) | 1.21 (0.72-1.89) | <.01 | 7 (8.5%) | 0.82 (0.59-1.14) | <.01 |
Atazanavir | 400 QD | 9 | 2 (22.2%) | 0.78 (0.35-1.37) | 0.71 | 0 (0.0%) | 0.59 (0.31-0.94) | 0.04 |
Atazanavir (boosted with ritonavir) | 300 QD | 18 | 4 (22.2%) | 0.97 (0.77-1.42) | 0.58 | 0 (0.0%) | 0.66 (0.51-0.85) | <.001 |
All Atazanavir | Â | 27 | 6 (22.2%) | 0.95 (0.53-1.42) | 0.76 | 0 (0.0%) | 0.65 (0.44-0.87) | <.0001 |
Lopinavir (boosted with ritonavir) | 400 BID | 16 | 3 (18.8%) | 1.21 (0.79-1.40) | 0.27 | 0 (0.0%) | 0.86 (0.74-1.18) | 0.32 |
Lopinavir (boosted with ritonavir) | 800 QD | 4 | 3 (75.0%) | 3.79 (1.44-4.86) | 0.25 | 0 (0.0%) | 0.99 (0.63-1.26) | 0.63 |
All Lopinavir | Â | 20 | 6 (30.0%) | 1.22 (0.79-1.81) | 0.11 | 0 (0.0%) | 0.86 (0.72-1.21) | 0.29 |
Efavirenz | 600 DQ | 16 | 6 (37.5%) | 0.95 (0.67-1.95) | 0.37 | 4 (25.0%) | 0.79 (0.57-1.27) | 0.63 |
Nevirapine | 200 BID | 11 | 5 (45.5%) | 1.41 (0.91-1.93) | 0.03 | 2 (18.2%) | 0.96 (0.84-1.37) | 0.46 |
Nevirapine | 400 QD | 8 | 5 (62.5%) | 2.08 (0.90-2.53) | 0.08 | 1 (12.5%) | 0.96 (0.72-1.40) | 0.95 |
All Nevirapine | Â | 19 | 10 (52.6%) | 1.62 (0.91-2.32) | <0.01 | 3 (15.8%) | 0.96 (0.81-1.37) | 0.47 |